News | Radiopharmaceuticals and Tracers | August 28, 2023

Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer

Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that they have signed a strategic collaboration to increase the global availability of actinium-225 (225Ac), a radioisotope that has the potential to treat a large variety of cancer indications. The companies will work together to increase near-term production of 225Ac[1] to support ongoing clinical trials and to ensure the large-scale supply of the radioisotope in the long term, addressing growing global demand. 

This collaboration will not have any immediate financial impact but has the potential to bring substantial revenues in the future to PanTera and, indirectly, to its two shareholders SCK CEN and IBA, a listed company on the Brussels stock exchange. 

Under this collaboration, both companies will use TerraPower Isotope’s natural decay method based on thorium-229 (229Th) and PanTera’s "Gamma route" based on the Rhodotron and radium-226 to produce 225Ac. 

225Ac is a promising alpha emitter for use in Targeted Alpha Therapy (TAT). A series of molecules that are currently under research, combined with 225Ac through further manufacturing, have the potential to treat a variety of cancers, targeting solid tumors, metastases, and systemic cancers such as leukemia. There are several clinical studies currently in progress, ranging from preclinical development through to phase 3 clinical trials. Whilst there is high demand, there is a scarcity of 225Ac. The collaboration between PanTera and TerraPower Isotopes is seeking to address this supply issue and support the clinical development of 225Ac based drugs as a potential treatment option for cancer. 

"We are excited to join forces with TerraPower Isotopes to increase the market availability of 225Ac. While continuing to prepare our unique technology for large-scale production of 225Ac, as from 2024 we will also offer the radioisotope to drug developers for their research and clinical trials, as well as to physicians for compassionate use. This volume would be equivalent to 50% of today’s supply and would underpin the wider development of these targeted alpha therapy radiopharmaceuticals as an effective treatment modality for cancer", commented Sven Van den Berghe, PanTera’s Chief Executive Officer. 

Scott Claunch, President of TerraPower Isotopes, added: "Consistent with TerraPower’s vision of developing innovative solutions to help fight disease using nuclear science, TerraPower Isotopes is thrilled to secure this collaboration with PanTera. Demand for 225Ac is expected to increase as more radiopharmaceutical treatments using 225Ac are developed to treat a variety of different types of cancers. This collaboration will help us supply this valuable material to the pharmaceutical industry and meet the growing global demand."  

For more information: 


Related Radioisotope Content 

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones   

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)     

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)       

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal       

Update on Unplanned Outage of the HFR Reactor       

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply       

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals       

How Nuclear Fusion is Revolutionizing Medical Isotope Production       

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes       

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE       

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m   


Related Content

News | Radiation Therapy

June 19, 2024 — RaySearch Laboratories AB announced a milestone in radiotherapy technology where RaySearch’s RayStation ...

Time June 19, 2024
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
News | Breast Imaging

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
News | Radiopharmaceuticals and Tracers

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
News | Information Technology

June 4, 2024 — International medical imaging IT and cybersecurity company Sectra has launched a new diagnostic IT module ...

Time June 04, 2024
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
Subscribe Now